CIA
OTLKW

Compass Ion Advisors’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

Compass Ion Advisors’s Portfolio OTLKW Stock Details OTLKW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$4K – 95
2021
Q2 		$4K Hold
10,000
– – ﹤0.01% 89
2021
Q1 		$10K Hold
10,000
– – ﹤0.01% 86
2020
Q4 		$2K Hold
10,000
– – ﹤0.01% 84
2020
Q3 		$1K Sell
10,000
-10,000
-50% -$1.9K ﹤0.01% 79
2020
Q2 		$5K Hold
20,000
– – ﹤0.01% 55
2020
Q1 		$3K Hold
20,000
– – ﹤0.01% 48
2019
Q4 		$2K Buy
+20,000
New +$2.07K ﹤0.01% 54

Other funds holding OTLKW

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Compass Ion Advisors's OTLKW Position: Q3 2021 in Review

Compass Ion Advisors sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q3 2021, closing a stake of 10,000 shares — an estimated $4K sold.

Compass Ion Advisors first reported a position in OTLKW in Q4 2019 and held it in 7 quarters. The position peaked at $10K in Q1 2021. 4 funds tracked by Wall St. Rank hold OTLKW as of Q3 2021.

  • Compass Ion Advisors reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q3 2021 after selling out during the quarter.
  • Compass Ion Advisors sold 10,000 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q3 2021, an estimated $4K.
  • Compass Ion Advisors first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q4 2019 and held it in 7 quarters.
  • Compass Ion Advisors's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $10K in Q1 2021.
  • 4 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q3 2021.

Based on Compass Ion Advisors's 13F filing for Q3 2021, filed 28 Oct 2021.